<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="editorial" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Biosci.</journal-id>
<journal-title>Frontiers in Molecular Biosciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Biosci.</abbrev-journal-title>
<issn pub-type="epub">2296-889X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1386623</article-id>
<article-id pub-id-type="doi">10.3389/fmolb.2024.1386623</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Biosciences</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Heparan sulfate-binding proteins in health and disease</article-title>
<alt-title alt-title-type="left-running-head">Gandy et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2024.1386623">10.3389/fmolb.2024.1386623</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gandy</surname>
<given-names>Lauren A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1960741/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Fuming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/981497/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Ding</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1200717/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pedersen</surname>
<given-names>Lars C.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1720249/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grobe</surname>
<given-names>Kay</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1151937/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Chunyu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1012954/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies</institution>, <institution>Rensselaer Polytechnic Institute</institution>, <addr-line>Troy</addr-line>, <addr-line>NY</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Glycobiology, Cell Growth and Tissue Repair Research Unit (Gly-CRRET)</institution>, <institution>Universit&#xe9; Paris-est Cr&#xe9;teil</institution>, <addr-line>Cr&#xe9;teil</addr-line>, <country>France</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Oral Biology</institution>, <institution>School of Dental Medicine</institution>, <institution>University of Buffalo</institution>, <institution>The State University of New York</institution>, <addr-line>Buffalo</addr-line>, <addr-line>NY</addr-line>, <country>United States</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Genome Integrity and Structural Biology Laboratory</institution>, <institution>National Institute of Environmental Health Sciences</institution>, <institution>National Institutes of Health</institution>, <addr-line>Durham</addr-line>, <addr-line>NC</addr-line>, <country>United States</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Institute of Physiological Chemistry and Pathobiochemistry</institution>, <institution>University of M&#xfc;nster</institution>, <addr-line>M&#xfc;nster</addr-line>, <country>Germany</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Department of Biology</institution>, <addr-line>Troy</addr-line>, <addr-line>NY</addr-line>, <country>United States</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Department of Chemistry and Chemical Biology</institution>, <institution>Rensselaer Polytechnic Institute</institution>, <addr-line>Troy</addr-line>, <addr-line>NY</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited and reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/819878/overview">Matthew P. DeLisa</ext-link>, Cornell University, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Chunyu Wang, <email>wangc5@rpi.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>11</volume>
<elocation-id>1386623</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>02</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>02</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Gandy, Zhang, Xu, Pedersen, Grobe and Wang.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Gandy, Zhang, Xu, Pedersen, Grobe and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front. Mol. Biosci." xlink:href="https://www.frontiersin.org/researchtopic/34875" ext-link-type="uri">Editorial on the Research Topic <article-title>Heparan sulfate-binding proteins in health and disease</article-title> </related-article>
<kwd-group>
<kwd>heparan sulfate (HS)</kwd>
<kwd>heparin</kwd>
<kwd>heparin-binding proteins</kwd>
<kwd>glycosaminoglycan (GAG)</kwd>
<kwd>fucoidan (FPS)</kwd>
<kwd>tauopathies</kwd>
<kwd>hedgehog autoprocessing</kwd>
<kwd>sepsis</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Glycoscience</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>This Research Topic is dedicated to a distinguished figure in the heparan sulfate (HS) field, Professor Robert J. Linhardt, whose contributions have left an indelible mark. Recognized globally for his pioneering research in HS and heparin, Dr. Linhardt&#x2019;s expertise has established him as a foremost authority in glycan analysis and sequencing with mass spectrometry, SPR, NMR, and nanopore technology. His notable achievements include being the first to sequence the glycosaminoglycan chain of a proteoglycan (<xref ref-type="bibr" rid="B7">Ly et al., 2011</xref>) and contributions to the synthesis of a glycosaminoglycan through metabolic engineering in <italic>E. coli</italic> (<xref ref-type="bibr" rid="B1">Badri et al., 2021</xref>). His work has been pivotal in the development of heparin-related drugs, including tinzaparin, aradaparin, enoxaparins, and low molecular weight heparins. During the 2007&#x2013;8 heparin contamination crisis, he spearheaded efforts to quickly identify the molecular culprit as oversulfated chondroitin sulfate (<xref ref-type="bibr" rid="B6">Liu et al., 2009</xref>). For this crucial contribution, he was named as one of the Scientific American 10: Guiding Science for Humanity in 2009 (<ext-link ext-link-type="uri" xlink:href="https://www.scientificamerican.com/article/scientific-american-10/">https://www.scientificamerican.com/article/scientific-american-10/</ext-link>). Dr. Linhardt&#x2019;s prolific output includes over 1,500 scientific publications with an H-factor of 138, and he holds more than 50 patents. Despite his recent retirement, he continues to publish valuable contributions to the field. His dedication to education is equally impressive, having mentored 81 Ph.D. and 15 master&#x2019;s students throughout his career, shaping the next-generation of scientists. He has been a mentor, colleague, and friend to many in the glycan field.</p>
<p>We are honored to carry on Dr. Linhardt&#x2019;s legacy by presenting six original articles and two reviews on HS-binding proteins (HSBP). HSBPs play essential roles in many physiological processes such as signal transduction, blood coagulation and immune response (<xref ref-type="bibr" rid="B9">M&#xf6;ckl, 2020</xref>). They are also critically involved in many diseases, including the cellular entry of pathogens, prion-like spread of amyloids, sepsis and nephritis.</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2023.1194293">Li et al.</ext-link> begins our Research Topic with an insightful review of structural mechanisms of HS/protein interaction, and how HS/protein interactions can be targeted by HS-based oligosaccharides and monoclonal antibodies, making an excellent case for using mAb to disrupt specific HSBP interactions; while <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2022.1083225">Faris et al.</ext-link> demonstrated the utility of a novel AlphaScreen assay for discovering inhibitors of protein-HS complexes, by targeting tau-HS interaction in Alzheimer&#x2019;s disease. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2023.1146685">Liao et al.</ext-link> presents an in-depth review of the involvement of HSBP in sepsis, highlighting the role of HMGB1 and the therapeutic potential of chemoenzymatically synthesized HS oligosaccharides in sepsis. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2023.1223972">Buijsers et al.</ext-link> demonstrated the protective effects of HS and fucoidan in kidney disease.</p>
<p>These are followed by an SAR study of marine sulfated glycan in antithrombin and PF4 binding for coagulation in <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2022.954752">Zhang et al.</ext-link> <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2022.1043713">Gandy et al.</ext-link> delved into why herpes virus requires the rare 3-<italic>O</italic>-sulfation modification for HS-mediated viral entry, discovering that the presence of this sulfation group shortens the HS length requirement for recognition by herpes glycoprotein D. Finally, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2023.1130064">Manikowski et al.</ext-link> demonstrated that HS plays an important role in the range of Hh ligand signaling in <italic>Drosophila</italic> wing development.</p>
<p>As shown in this excellent Research Topic collection, HSBPs are involved in a large number of biological and pathological processes. The field of HSBP is expanding rapidly, as our knowledge of HS and HSBPs in health and disease grows. Since the characterization of antithrombin and HS in the early 1980s (<xref ref-type="bibr" rid="B10">Petitou et al., 2003</xref>; <xref ref-type="bibr" rid="B12">Shriver et al., 2012</xref>), investigations of HS-HSBP interactions have provided crucial insights into some of the most complex diseases, such as Alzheimer&#x2019;s disease (<xref ref-type="bibr" rid="B3">Holmes et al., 2013</xref>; <xref ref-type="bibr" rid="B14">Zhao et al., 2020</xref>; <xref ref-type="bibr" rid="B8">Mah et al., 2021</xref>), HPV (<xref ref-type="bibr" rid="B4">Johnson et al., 2009</xref>; <xref ref-type="bibr" rid="B11">Shafti-Keramat et al., 2003</xref>), and SARS-COV-2 (<xref ref-type="bibr" rid="B2">Clausen et al., 2020</xref>; <xref ref-type="bibr" rid="B13">Yue et al., 2021</xref>; <xref ref-type="bibr" rid="B5">Kearns et al., 2022</xref>). Further characterization of the involvement of HS/HSBP in health and disease will provide novel mechanistic insights and hopefully therapeutic opportunities to improve human health.</p>
</body>
<back>
<sec id="s1">
<title>Author note&#x2019;s</title>
<p>This article is dedicated to Dr. Robert J. Linhardt.</p>
</sec>
<sec id="s2">
<title>Author contributions</title>
<p>LG: Writing&#x2013;original draft, Writing&#x2013;review and editing. FZ: Writing&#x2013;original draft, Writing&#x2013;review and editing. DX: Writing&#x2013;review and editing. LP: Writing&#x2013;review and editing. KG: Writing&#x2013;review and editing. CW: Writing&#x2013;original draft, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s3">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s4">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec sec-type="disclaimer" id="s5">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Awofiranye</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Datta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Complete biosynthesis of a sulfated chondroitin in <italic>Escherichia coli</italic>
</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>1389</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-21692-5</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clausen</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Sandoval</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Spliid</surname>
<given-names>C. B.</given-names>
</name>
<name>
<surname>Pihl</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Perrett</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>Painter</surname>
<given-names>C. D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2</article-title>. <source>Cell</source> <volume>183</volume> (<issue>4</issue>), <fpage>1043</fpage>&#x2013;<lpage>1057</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.09.033</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>B. B.</given-names>
</name>
<name>
<surname>DeVos</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Kfoury</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jacks</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yanamandra</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>110</volume> (<issue>33</issue>), <fpage>E3138</fpage>&#x2013;<lpage>E3147</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1301440110</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Kines</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>J. N.</given-names>
</name>
<name>
<surname>Lowy</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Schiller</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>P. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus</article-title>. <source>J. Virol.</source> <volume>83</volume> (<issue>5</issue>), <fpage>2067</fpage>&#x2013;<lpage>2074</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.02190-08</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kearns</surname>
<given-names>F. L.</given-names>
</name>
<name>
<surname>Sandoval</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Casalino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Clausen</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Spliid</surname>
<given-names>C. B.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Spike-heparan sulfate interactions in SARS-CoV-2 infection</article-title>. <source>Curr. Opin. Struct. Biol.</source> <volume>76</volume>, <fpage>102439</fpage>. <pub-id pub-id-type="doi">10.1016/j.sbi.2022.102439</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Linhardt</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Lessons learned from the contamination of heparin</article-title>. <source>Nat. Product. Rep.</source> <volume>26</volume> (<issue>3</issue>), <fpage>313</fpage>&#x2013;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1039/b819896a</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ly</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leach</surname>
<given-names>F. E.</given-names>
</name>
<name>
<surname>Laremore</surname>
<given-names>T. N.</given-names>
</name>
<name>
<surname>Toida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Amster</surname>
<given-names>I. J.</given-names>
</name>
<name>
<surname>Linhardt</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>The proteoglycan bikunin has a defined sequence</article-title>. <source>Nat. Chem. Biol.</source> <volume>7</volume> (<issue>11</issue>), <fpage>827</fpage>&#x2013;<lpage>833</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.673</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mah</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The sulfation code of tauopathies: heparan sulfate proteoglycans in the prion like spread of tau pathology</article-title>. <source>Front. Mol. Biosci.</source> <volume>8</volume>, <fpage>671458</fpage>. <pub-id pub-id-type="doi">10.3389/fmolb.2021.671458</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>M&#xf6;ckl</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The emerging role of the mammalian glycocalyx in functional membrane organization and immune system regulation</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>8</volume>, <fpage>253</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2020.00253</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petitou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Casu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lindahl</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>1976&#x2013;1983, a critical period in the history of heparin: the discoveryof the antithrombin binding site</article-title>. <source>Biochimie</source> <volume>85</volume> (<issue>1</issue>), <fpage>83</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/S0300-9084(03)00078-6</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shafti-Keramat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Handisurya</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kriehuber</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Meneguzzi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Slupetzky</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kirnbauer</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses</article-title>. <source>J. virol.</source> <volume>77</volume> (<issue>24</issue>), <fpage>13125</fpage>&#x2013;<lpage>13135</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.77.24.13125-13135.2003</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shriver</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Capila</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Venkataraman</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sasisekharan</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Heparin and heparan sulfate: analyzing structure and microheterogeneity</article-title>. <source>Handb. Exp. Pharmacol.</source> (<issue>207</issue>), <fpage>159</fpage>&#x2013;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-23056-1_8</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Faulkner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Heparan sulfate facilitates spike protein-mediated SARS-CoV-2 host cell invasion and contributes to increased infection of SARS-CoV-2 G614 mutant and in lung cancer</article-title>. <source>Front. Mol. Biosci.</source> <volume>8</volume>, <fpage>649575</fpage>. <pub-id pub-id-type="doi">10.3389/fmolb.2021.649575</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>3-O-Sulfation of heparan sulfate enhances tau interaction and cellular uptake</article-title>. <source>Angew. Chem. - Int. Ed.</source> <volume>59</volume> (<issue>5</issue>), <fpage>1818</fpage>&#x2013;<lpage>1827</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201913029</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>